Loading stock data…
CYTK
$75.21-1.88 (-2.44%)
Market OpenUpdated 3:03 PM EDT
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytokinetics, Incorporated in the Healthcare sector is trading at $75.21. The stock is currently near its 52-week high of $80.20, remaining 29.3% above its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why CYTK maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$75.21
Potential Upside
5%
Whystock Fair Value$78.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target$96.05+27.7%
Range$69.00 – $136.00
Fundamentals
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
91.92%
Volume
Today's trading volume
3.04M
Recent News
Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC Says
Cytokinetics' (CYTK) rapid growth of the Myqorzo drug and peak US opportunity in obstructive hypertr
Cytokinetics (CYTK) Hits 52-Week High as Revenues Soar Over 1,000%
Cytokinetics Inc. (NASDAQ:CYTK) is one of the 10 Stocks Turning Heads With Double-Digit Gains. Cytokinetics rallied for a second day on Tuesday, to hit a new 52-week high, as investors gobbled up shares following a stellar first quarter revenue performance, supported by the strong sales for its newly-launched heart disease treatment, myqorzo. At intra-day trade, […]
Cytokinetics Q1 Earnings Call Highlights
Cytokinetics (NASDAQ:CYTK) highlighted the first full quarter as a commercial-stage company during its first-quarter 2026 earnings call, pointing to early U.S. demand for its newly launched hypertrophic cardiomyopathy (HCM) drug MYQORZO, a recent European approval, and positive top-line results from
Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial
Cytokinetics (NASDAQ:CYTK) reported positive top-line results from ACACIA-HCM, a pivotal Phase 3 trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). On a conference call, President and CEO Robert Blum said the study showed “statistically signif
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -0.20% and +173.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?